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Abstract
Aims The aim of this study was to assess the prognostic value of chronic kidney disease (CKD) in relation to ischaemic stroke,
intracranial haemorrhage, major bleeding, and all-cause death in heart failure patients without atrial fibrillation.
Methods and results In this observational cohort study, heart failure patients without atrial fibrillation were identified using
Danish nationwide registries. Risk of stroke, major haemorrhage, and death were calculated after 1 and 5 years to compare
patients with and without CKD, ±dialysis [dialysis: CKD with renal replacement therapy (CKD-RRT); no dialysis: CKD-no RRT].
A total of 43 199 heart failure patients were included, among which 0.8% had CKD-RRT and 5.9% had CKD-no RRT. When com-
pared with heart failure patients without CKD, both CKD-RRT and CKD-no RRT were associated with a higher 5 year rate of
major bleeding (CKD-RRT: adjusted hazard ratio (aHR): 2.91, 95% confidence interval (CI): 2.29 to 3.70; CKD-no RRT: aHR:
1.28, 95% CI: 1.13 to 1.45) and all-cause death (CKD-RRT: aHR: 2.40, 95% CI: 2.07 to 2.77; CKD-no RRT: aHR: 1.63, 95% CI:
1.55 to 1.73). For the endpoints of ischaemic stroke and intracranial bleeding, only CKD-no RRT was associated with signifi-
cantly higher 5 year rates (ischaemic stroke: aHR: 1.31, 95% CI: 1.13 to 1.52; intracranial haemorrhage: aHR: 1.66, 95% CI:
1.04 to 2.65).
Conclusions Compared with patients without CKD, among incident heart failure patients without atrial fibrillation, CKD both
with and without dialysis was associated with a higher rate of major bleeding and all-cause death. Only CKD-no RRT was as-
sociated with a higher rate of ischaemic stroke and intracranial bleeding.
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Introduction
Heart failure (HF) and chronic kidney disease (CKD) often co-
exist.1–3 Among HF patients with concomitant CKD, mortality
and morbidity are high.4,5 Nonetheless, there are limited data
on the risk of stroke and bleeding, especially among HF pa-
tients without atrial fibrillation (AF).
In the HF population, thromboembolic risk stratification is
evolving to help identify ‘high-risk’ subjects, who may be
targeted for more regular review and follow-up, as well as
more intensified cardiovascular prevention strategies.6
Chronic kidney disease has been associated with an increased
risk of stroke in the general population,7 but whether CKD is a
prognostic factor of stroke in patients with HF has not been
investigated. Also, CKD has been associated with an increased
risk of haemorrhagic stroke and major bleeding in patients
with cardiovascular disease,8,9 although this has not been
specifically described in the HF population. As patients with
CKD are a heterogeneous group, it may be necessary to sub-
divide these patients according to disease severity, e.g. CKD
requiring dialysis, for optimal assessment of risks and clinical
risk stratification.
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The objective of the present observational cohort study
was to assess the prognostic value of CKD in relation to the
risk of ischaemic stroke, intracranial haemorrhage, major
bleeding, and all-cause death in HF patients without AF, using
Danish nationwide administrative registries. We hypothe-
sized that, compared with patients without CKD, in a popula-
tion of incident HF patients without AF, CKD {both CKD with
dialysis [CKD with renal replacement therapy (CKD-RRT)]
and without dialysis [CKD-no RRT]} would be associated with
a higher risk of ischaemic stroke, intracranial haemorrhage,
major bleeding, and all-cause death, also when controlling
for concomitant cardiovascular risk factors.
Methods
Registry data sources
We used data from three nationwide registries: (i) the Danish
National Patient Registry,10 which has registered all hospital
admissions along with diagnoses since 1977 and codes all di-
agnoses according to the 10th revision of the International
Classification of Diseases (ICD-10) since 1994; (ii) the National
Prescription Registry,11 which contains data on all prescrip-
tions dispensed from Danish pharmacies since 1994, coded
according to the Anatomical Therapeutic Chemical Classifica-
tion System; and (iii) the Danish Civil Registration System,
which holds information on date of birth, migration, vital sta-
tus, date of death, and sex of all persons living in Denmark.12
Data were linked via a unique personal identification number
used across all Danish national registries. Information from
the three registries was retrieved until 31 December 2014.
These registries have previously been validated,10–12 and
the diagnoses of HF, stroke, and CKD were all found to have
high validity.13–15
Study population
The study population was identified as inpatient or outpa-
tients aged>50 years, diagnosed with a primary discharge di-
agnosis of incident (first-time diagnosis) HF in the period 1
January 2000 to 31 July 2014. Chronic kidney disease was de-
fined as a diagnosis of CKD-RRT (defined as a diagnosis of CKD
and a concomitant procedure code for dialysis) or CKD-no RRT
(defined as a diagnosis of CKD and no concomitant procedure
code for dialysis) between 1994 and time of HF diagnosis (for
ICD-10 codes used in the definitions of CKD-RRT and CKD-no
RRT, see Table S1). Chronic kidney disease status was assessed
at the time of the HF diagnosis, and status could not change
throughout the follow-up period. To restrict to patients with-
out AF, we excluded those who had a prior diagnosis of AF or
atrial flutter between 1994 and time of HF diagnosis. We ex-
cluded patients treated with a vitamin K antagonist within
6 months prior to the HF diagnosis to avoid considering effect
modification by anticoagulation therapy, and because such
patients may have AF that is diagnosed but unregistered. Ad-
ditionally, we excluded patients with a prior procedure code
for kidney transplantation, as this small patient group may
be difficult to categorize with the available data from the reg-
istries. Lastly, patients with a diagnosis of cancer within 5 years
before HF diagnosis were excluded, because cancer patients
represents a subgroup with high stroke risk16 and specialized
thromboprophylactic treatment regimens.
Additional co-morbidities were assessed at time of HF di-
agnosis and identified using the Danish National Patient Reg-
istry and the Danish National Prescription Registry.
Ascertainment of baseline medication status was based on
medication purchase in a 45 day window before or after
the date of HF diagnosis to express the status in the follow-
up period. ICD codes and Anatomical Therapeutic Chemical
codes used to define co-morbidities and medical therapy
are provided in Table S1.
Outcomes
The primary endpoints were defined as a diagnosis of ischae-
mic stroke or bleeding. Bleeding was included as intracranial
haemorrhage and major bleeding (combined endpoint of in-
tracranial haemorrhage, gastrointestinal bleeding, and extra-
cranial or unclassified major bleeding). All-cause death was
also included as an outcome, because of the high mortality
among HF patients and the appertaining possibility of distor-
tion from competing risks, and the fact that in administrative
registries some deaths may be due to undiagnosed stroke or
bleeding.
Statistical methods
Baseline characteristics were described separately for pa-
tients without CKD, CKD-no RRT, and CKD-RRT using means
and standard deviation for continuous variables, and propor-
tions for categorical variables. Time-to-event analysis was
used to describe the association between CKD status (CKD-
no RRT or CKD-RRT) and the risk of ischaemic stroke, intracra-
nial haemorrhage, major bleeding, or all-cause death. Time at
risk was measured from baseline date (date of HF diagnosis)
and until an event of ischaemic stroke, intracranial haemor-
rhage, major bleeding, all-cause death, emigration, or end
of study (31 December 2014), whichever came first. Addition-
ally, patients were censored if they initiated anticoagulant
therapy during the follow-up period.
Crude cumulative incidence curves for all endpoints ac-
cording to CKD status (no CKD, CKD-no RRT, or CKD-RRT)
were constructed based on the Aalen–Johansen estimator17
for competing risk data. We have previously advocated risks
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(probabilities) rather than rates for assessing associations in
an HF population, as risks lead to statements of greater clin-
ical and prognostic relevance when faced with a high compet-
ing mortality risk.18 However, strong differential competing
mortality across exposure levels can lead to counterintuitive
findings on a risk scale, which is a major concern for CKD as
an exposure. Therefore, we reported associations in terms
of (Cox model) hazard ratios (HRs) after 1 and 5 years of
follow-up. Following the suggestions by Andersen et al.19 of
considering both risk and rate assessments, we repeated
the analysis on a risk (ratio) scale; see the Supporting Infor-
mation for methodological details.
For the main analysis, Cox regression was used to calculate
1 and 5 year HRs of the endpoints according to the status of
CKD (CKD-no RRT or CKD-RRT), with patients without CKD as
reference group. Concomitant baseline co-morbidities such
as hypertension, diabetes, vascular disease, and prior ischae-
mic stroke are well-known prognostic factors of stroke and
bleeding in other heart diseases.20,21 Thus, we fitted the
Cox models after adjusting for these clinical factors, including
age and sex. These prognostic factors are also included in the
CHA2DS2-VASc [congestive HF, hypertension, age ≥ 75 years
(doubled), diabetes, stroke/transient ischaemic
attack/thromboembolism (doubled), vascular disease (prior
myocardial infarction, peripheral artery disease, or aortic
plaque), age 65–75 years, sex category (female)] score; thus,
we basically adjusted for components of this score. Addition-
ally, as antiplatelet therapy may modify the association
between CKD and risk of the endpoints, we also included
use of antiplatelet therapy in the main adjusted Cox model.
Analyses were performed using Stata version 13 (Stata
Corporation, College Station, TX, USA). Results are reported
with 95% confidence intervals (CIs).
Supplementary and sensitivity analyses
As some patients might have a diagnosis of AF shortly after
the HF diagnosis, a sensitivity analysis was performed by re-
peating the HR calculations after extending the definition of
concomitant AF at baseline; AF patients were identified if
they had a prior diagnosis code for AF at baseline (at time
of HF diagnosis) or received a diagnosis code for AF within
30 days after the HF diagnosis. Furthermore, some patients
are diagnosed with AF during follow-up; thus, to investigate
whether the inclusion of AF patients affects our main results,
we performed another sensitivity analysis after censoring pa-
tients who are diagnosed with AF during follow-up.
In a supplementary analysis, to investigate whether the
chosen well-known risk factors are correctly included in the
main adjusted model, additional models were constructed
adjusting for age and sex only (model 1) and age, sex, and each
individual risk factors (Models 2–6). The results of these addi-
tional models are presented in the Supporting Information.
Ethical considerations
No ethical approval is required for studies based on data from
administrative Danish registries. The study was approved by
the Danish Data Protection Agency (J. No. File No. 2015-57-
0001). The study was conducted and reported in accordance
with the STROBE (Strengthening the Reporting of Observa-
tional Studies in Epidemiology) recommendations.
Results
The study population comprised 43 199 HF patients aged
>50 years, among which 0.8% had CKD-RRT and 5.9% had
CKD-no RRT at baseline (Figure 1). The median follow-up time
for ischaemic stroke or all-cause death was 2.3 years (inter-
quartile range 0.5 to 5.3).
Baseline patient characteristics are summarized in Table 1.
Mean age was similar among HF patients without CKD and
CKD-no RRT, but lower for patients with CKD-RRT. Patients
with CKD had more prevalent prior stroke/transient ischae-
mic attack and major bleeding than did patients without
CKD; also, the prevalence of diabetes, hypertension, and vas-
cular disease was higher in patients with CKD, as expected.
The number of events and the absolute risk of ischaemic
stroke, intracranial haemorrhage, major bleeding, and all-
cause death in each patient group after 1 and 5 years of
follow-up are shown in Table 2. For patients with CKD-RRT,
the absolute risk of all endpoints was high, after both 1 and
5 years of follow-up (ischaemic stroke: 2.5 and 6.9; intracra-
nial haemorrhage: 1.3 and 1.3; major bleeding: 13.0 and
24.9; all-cause death: 32.8 and 69.7, respectively). Notably,
the risk of all-cause death was very high in all patient groups
after 5 years of follow-up (48.5%, 68.2%, and 69.7%, for pa-
tients without CKD, CKD-no RRT, and CKD-RRT, respectively).
The number of intracranial haemorrhage events was low in
our study population. Crude cumulative incidence curves for
all endpoints demonstrate a steady increase during follow-
up, as seen in Figure 2.
Multivariable analysis
In the Cox regression analysis adjusted for concomitant
prognostic factors, when compared with HF patients without
CKD, both CKD-RRT and CKD-no RRT were associated with a
higher 5 year rate of major bleeding (CKD-RRT: adjusted HR:
2.91, 95% CI: 2.29 to 3.70; CKD-no RRT: adjusted HR: 1.28,
95% CI: 1.13 to 1.45) and all-cause death (CKD-RRT: adjusted
HR: 2.40, 95% CI: 2.07 to 2.77; CKD-no RRT: adjusted HR:
1.63, 95% CI: 1.55 to 1.73; Figure 3). For the endpoints of
ischaemic stroke and intracranial bleeding, only CKD-no
RRT was associated with significantly higher 5 year rates
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(ischaemic stroke: adjusted HR: 1.31, 95% CI: 1.13 to 1.52;
intracranial haemorrhage: adjusted HR: 1.66, 95% CI: 1.04
to 2.65).
Similar results were obtained after 1 year of follow-up.
The 1 and 5 year relative risks of all endpoints, comparing
patients with no CKD, CKD-no RRT, and CKD-RRT, are shown
in Tables S2 and S3. We found similar, although slightly lower,
crude associations as in the rate-based calculations, but the as-
sociations attenuated after adjustment for other cardiovascular
prognostic factors, especially for the ischaemic stroke endpoint.
Supplementary and sensitivity analyses
In the sensitivity analysis excluding patients with an AF diag-
nosis at baseline or within 30 days after the HF diagnosis,
findings were similar to those of the main analysis (Table
S4). In the sensitivity analysis in which patients were cen-
sored if they were diagnosed with AF during follow-up, we
found similar results as in the main analysis (Table S5).
Discussion
In this nationwide cohort study of HF patients without diag-
nosed AF and not taking anticoagulant therapy, we found
higher rates of intracranial haemorrhage, major bleeding,
and all-cause death among HF patients with CKD-RRT and
CKD-no RRT compared with patients without CKD, even after
extensive adjustment for concomitant cardiovascular risk fac-
tors. For the endpoint ischaemic stroke, only CKD-no RRT was
associated with a higher risk.
To our knowledge, this is the first study to evaluate the
prognostic value of CKD in relation to ischaemic stroke, intra-
cranial haemorrhage, major bleeding, and all-cause death in
an HF population without diagnosed AF.
The current evidence on the risk of stroke in subgroups of
HF patients without AF is very limited.22–24 Our finding of an
increased risk of ischaemic stroke in patients with CKD-no
Table 1 Baseline characteristics of study population according to













n, % (n) 93.3 (40 307) 5.9 (2564) 0.8 (328)
Sex (female), % (n) 44.5 (17 947) 37.6 (964) 33.8 (111)





12.6 (5082) 20.1 (515) 19.5 (64)
Previous intracranial
haemorrhage
1.1 (460) 1.1 (27) 1.5 (5)
Previous major
bleeding
18.3 (7375) 32.3 (827) 37.5 (123)
Diabetes 12.8 (5140) 37.8 (970) 32.3 (106)
Hypertension 30.8 (12 416) 61.4 (1574) 72.0 (236)
Vascular disease 30.7 (12 384) 43.1 (1104) 45.4 (149)
Previous myocardial
infarction
25.3 (10 180) 31.0 (794) 30.8 (101)
Liver disease 0.4 (172) 1.2 (30) 1.2 (4)
Hyperthyroidism 2.6 (1065) 2.6 (66) 3.4 (11)
COPD 13.4 (5413) 16.5 (424) 11.0 (36)
Medication, % (n)
ACE-inhibitors 53.3 (21 498) 39.5 (1014) 39.9 (131)
Angiotensin receptor
blocker
10.7 (4317) 17.4 (446) 16.8 (55)
Beta-blockers 45.9 (18 480) 47.9 (1228) 57.9 (190)
Aldosterone
antagonists
23.5 (9475) 18.4 (471) 3.7 (12)
Non-loop diuretics 39.6 (15 975) 33.3 (854) 6.1 (20)
Loop diuretics 65.0 (26 182) 74.8 (1917) 58.2 (191)
Statins 32.4 (13 068) 37.9 (973) 31.1 (102)
NSAIDs 13.8 (5577) 13.5 (346) 4.0 (13)
Aspirin 48.6 (19 586) 49.0 (1256) 38.7 (127)
Thienopyridines 12.3 (4960) 12.6 (323) 13.7 (45)
ACE, angiotensin-converting-enzyme; COPD, chronic obstructive
pulmonary disease; NSAIDs, non-steroidal anti-inflammatory
drugs; SD, standard deviation.
Figure 1 Flowchart of patients included in the final study population.
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RRT is similar to previous findings from non-HF populations.9,25
As the aim of our study was to examine the prognostic value of
CKD in relation to stroke, major bleeding, and mortality in HF,
we can only speculate on the aetiological explanations for our
observations. For example, the increased stroke risk associated
with CKD may be explained by the coexistence of platelet dys-
function, endothelial damage/dysfunction, and prothrombotic
and inflammatory state, which is often seen in patients with
CKD as well as in HF.26 Additionally, the increased risk of bleed-
ing may be due to platelet dysfunction, prolonged bleeding
time, and small vessel disease associated with CKD.27,28
Overall, CKD may be associated with adverse outcomes in
HF, as it is a marker of more severe HF, greater symptom bur-
den, and/or coexistent disease.1,2,29 The poorer survival in pa-
tients with CKD and HF may also reflect the reduced likelihood
of being prescribed evidence-based therapies,29,30 as CKD is of-
ten viewed as a contraindication to some therapies,2,29 includ-
ing thromboprophylactic therapies.31 This is correspondingly
reflected in randomized trials testing the efficacy and safety
of therapies, where patients with CKD are often excluded,
resulting in clinicians being challenged in how to choose the
optimal treatment for these patients.
Table 2 Event numbers and absolute risks of all endpoints after 1 and 5 years of follow-up, according to chronic kidney disease status
Endpoint
1 year of follow-up 5 years of follow-up
No. of events Absolute riska (%) No. of events Absolute riska (%)
Ischaemic stroke
No chronic kidney disease 1112 2.9 2391 7.1
Chronic kidney disease without dialysis 107 4.4 205 9.4
Chronic kidney disease with dialysis 8 2.5 17 6.9
Intracranial haemorrhage
No chronic kidney disease 89 0.2 214 0.7
Chronic kidney disease without dialysis 10 0.4 21 1.0
Chronic kidney disease with dialysis 4 1.3 4 1.3
Major bleedingb
No chronic kidney disease 1728 4.6 3905 11.7
Chronic kidney disease without dialysis 152 6.3 289 13.4
Chronic kidney disease with dialysis 40 13.0 69 24.9
All-cause death
No chronic kidney disease 7944 20.8 16 290 48.5
Chronic kidney disease without dialysis 860 35.0 1487 68.2
Chronic kidney disease with dialysis 101 32.8 187 69.7
aTaking into account competing risks of death (Aalen–Johansen estimator).
bCombined endpoint of intracranial haemorrhage, gastrointestinal bleeding, extracranial, or unclassified major bleeding.
Figure 2 Crude cumulative incidence of all endpoints according to chronic kidney disease status (note the varying range of the y-axes). Abbreviations:
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With the focus on refining risk stratification, our findings
indicate that CKD may be an important prognostic factor in
high-risk patients with HF without AF. However, in the pres-
ent study, only CKD-no RRT was associated with an increased
risk of ischaemic stroke. This probably reflects the fact that
patients with CKD-RRT are on dialysis (and receive low-molec-
ular-weight heparin), which may reduce their thrombotic risk.
Thus, in patients with CKD and HF, individualized risk assess-
ment according to disease severity is necessary to optimize
cardiovascular prevention strategies.
We provided both risk/probability (risk ratio) and rate (HR) as-
sessments of the associations.19While risk and rate assessments
are traditionally thought of as being equivalent, they can be fun-
damentally different in the face of competing mortality risk.32 In
the present study, associations were attenuated when viewed
on a risk scale. This is important information from a clinical per-
spective, as it may indicate a smaller absolute potential of pre-
vention strategies among patients with CKD and HF than
otherwise suggested by the HRs.
Strengths and limitations
The large sample size uniquely possible with this type of cohort
study minimizes the risk of random error. Selection into the
study was not an issue, as we investigated a nationwide popu-
lation cohort of incident HF patients without AF using adminis-
trative data, which also implies very limited loss to follow-up.
The diagnosis of HF has previously been validated with a
sensitivity of 29%, a specificity of 99%, and a positive predic-
tive value of 81–100%15,33; thus, we likely did not capture all
patients with HF and also cannot be certain that all patients
identified as having HF had definite HF. Nonetheless, this
most likely applies equally to both exposed and non-exposed,
and the suboptimal positive predictive value is therefore not
a likely explanation for the observed associations. Also, we in-
cluded only patients with a primary discharge diagnosis of HF
to optimize the probability of including only correctly identi-
fied patients with HF.
Patients with CKD were identified using ICD-10 codes in
the Danish registries, which have also been used in previous
registry-based studies of patients with CKD.9,25 However, we
did not have access to biomarkers, and therefore, CKD could
be under-reported, as a measurement outside normal ranges
might not necessarily trigger a diagnosis in the registries. We
cannot rule out that some patients might have had undiag-
nosed AF, because (any) heart disease is associated with an
increased risk of developing AF; however, censoring for a di-
agnosis of AF during follow-up did not change our main con-
clusions. The diagnosis of ischaemic stroke has also been
validated and found to have a positive predictive value of
80–90%.13,34 We included unspecified stroke in the definition
of ischaemic stroke, as many such strokes are of ischaemic or-
igin.13 However, we cannot rule out that some of these
strokes were haemorrhagic strokes and, thus, misclassified
as ischaemic strokes. Nonetheless, such issues with diagnos-
tic coding are likely to apply equally among exposed and
non-exposed, and our findings are, therefore, unlikely to be
explained by information bias.
We investigated whether the presence of CKD was associ-
ated with ischaemic stroke, intracranial haemorrhage, major
bleeding, and all-cause death in patients with HF, and there-
fore, we adjusted for well-known cardiovascular prognostic fac-
tors for stroke and bleeding. This was not an attempt to adjust
for confounding and hereby explore the potential causal rela-
tionship between the exposure and outcomes, but to elucidate
the potential added predictive ability of the exposure in rela-
tion to risk stratification of patients with HF after adjustment
for other possible prognostic factors, essentially those included
in the previously investigated CHA2DS2-VASc score.
6 As the fo-
cus was on the prognostic value of a diagnosis of CKD in relation
to stroke and bleeding, not its causal role, potential confound-
ing by other stroke and bleeding risk factors (e.g. blood pres-
sure level, smoking, body mass index, and lipid status) is of
Figure 3 Hazard rate ratios of all endpoints after 1 and 5 years of follow-up, according to chronic kidney disease status (reference group: patients
without chronic kidney disease). Abbreviations: 95% CI, 95% confidence interval; FUP, follow-up. Analysis adjusted for sex (binary), age (continuous),
hypertension (binary), diabetes (binary), prior stroke/transient ischaemic attack (binary), vascular disease (binary), and antiplatelet therapy (binary).
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lesser concern in this study. Additionally, as the focus of the
study was on the prognostic value in incident HF patients, a
change in CKD status during follow-up was less important.
The data used in this study were not collected for the primary
purpose of this study, which is a limitation with respect to miss-
ing information about selected variables that could have been
of interest, e.g. lifestyle factors. However, the Danish nation-
wide registries have been acknowledged as a valuable tool
and data source for epidemiological research.35,36
Generalizability of the study results
The study population consisted only of patients aged
>50 years, and HF in persons aged <50 years might repre-
sent a different group of patients, for example, patients with
congenital heart disease. Accordingly, our findings may not
apply to younger HF patients. Additionally, we were unable
to distinguish between HF with preserved and reduced ejec-
tion fraction or to estimate the functional classification, as
we did not have access to echocardiograms, so we cannot
be sure that the results apply to patients with preserved
and reduced ejection fraction. Lastly, the study was carried
out as a nationwide study in the Danish population, which
ethnically is fairly homogeneous; thus, future studies are
needed to evaluate if our findings hold in more ethnically di-
verse populations.
In conclusion, compared with patients without CKD,
among incident HF patients without AF, CKD, despite severity,
was associated with a higher rate of major bleeding and all-
cause death. Only CKD-no RRT was associated with higher
rates of ischaemic stroke and intracranial bleeding. Chronic
kidney disease may have prognostic value when considering
cardiovascular prevention strategies in the HF population
without AF.
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follow-up (using different adjusted models), according to
chronic kidney disease status (reference group: patients
without chronic kidney disease).
Table S7. Hazard rate ratios of all endpoints after 5 years of
follow-up (using different adjusted models), according to
chronic kidney disease status (reference group: patients
without chronic kidney disease).
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